Immunohistochemical analysis of C/EBPα in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: A correlative study of E3590

Lung Cancer

Volumn 56, Issue 1, 2007, Pages 97-103

  Costa, Daniel B ^a,b   Li, Sigui ^b,c   Kocher, Olivier ^a   Feins, Richard H ^d   Keller, Steven M ^e   Schiller, Joan H ^f   Johnson, David H ^g   Tenen, Daniel G ^a,b   Halmos, Balazs ^h  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e MONTEFIORE MEDICAL CENTER   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g VANDERBILT UNIVERSITY   (United States)

^h CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

C EBP ; Immunohistochemistry; Lung cancer; Non small cell lung cancer; Squamous cell carcinoma; Survival; Transcription factor

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CISPLATIN; ETOPOSIDE; K RAS PROTEIN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DOWN REGULATION; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATHOGENESIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; COHORT STUDIES; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 33847676808     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.11.023     Document Type: Article

References (36)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics, 2006. CA Cancer J Clin. 56 (2006) 106-130
2. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 111 (1997) 1710-1717
3. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P., Vansteenkiste J., and International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 350 4 (2004) 351-360
4. Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C., et al., National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR. 10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 352 25 (2005) 2589-2597
5. Strauss G.M., Herndon J., Maddaus M.A., Johnstone D.W., Johnson E.A., Watson D.M., et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer: report of CALGB protocol 9633. J Clin Oncol 22 14S (2004) 621s
6. Douillard J., Rosell R., Delena M., Legroumellec A., Torres A., and Carpagnano F. ANITA: phase III adjuvant vinorelbine and cisplatin versus observation in completely resected (stage I-III) non-small cell lung cancer patients: final results after 70-month median follow-up. J Clin Oncol 23 16S (2005) 624s
7. Schiller J.H., Adak S., Feins R.H., Keller S.M., Fry W.A., Livingston R.B., et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. J Clin Oncol 19 2 (2001) 448-457
8. Sekido Y., Fong K.M., and Minna J.D. Molecular genetics of lung cancer. Annu Rev Med 54 (2003) 73-87
9. Gonzalez-Quevedo R., Iniesta P., Moran A., de Juan C., Sanchez-Pernaute A., Fernandez C., et al. Cooperative role of telomerase activity and p16 expression in the prognosis of non-small-cell lung cancer. J Clin Oncol 20 1 (2002) 254-262
10. Mitsudomi T., Hamajima N., Ogawa M., and Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 6 10 (2000) 4055-4063
11. Tammemagi M.C., McLaughin J.R., and Bull S.B. Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers. Cancer Epidemiol Biomarkers Prev 8 (1999) 625-634
12. Slebos R.J., Kibbelaar R.E., Dalesio O., Kooistra A., Stam J., Meijer C.J., et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323 (1990) 561-565
13. Kanematsu T., Yano S., Uehara H., Bando Y., and Sone S. Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. Oncol Res 13 5 (2003) 289-298
14. Huang C., Liu D., Masuya D., Nakashima T., Kameyama K., Ishikawa S., et al. Clinical application of biological markers for treatments of resectable non-small-cell lung cancers. Br J Cancer 92 7 (2005) 1231-1239
15. Ferraro B., Bepler G., Sharma S., Cantor A., and Haura E.B. EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer. J Clin Oncol 23 9 (2005) 1921-1926
16. Lu C., Soria J.C., Tang X., Xu X.C., Wang L., Mao L., et al. Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol 22 22 (2004) 4575-4583
17. McKnight S.L. McBindall: a better name for CCAAT/enhancer binding proteins?. Cell 107 (2001) 259-261
18. Lekstrom-Himes J., and Xanthopoulos K.G. Biological role of the CCAAT/enhancer binding protein family of transcription factors. J Biol Chem 273 (1998) 28545-28548
19. Pabst T., Mueller B.U., Zhang P., Radomska H.S., Narravula S., Schnittger S., et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-in acute myeloid leukemia. Nat Genet 17 (2001) 263-270
20. Pabst T., Mueller B.U., Harakawa N., Schoch C., Haferlach T., Behre G., et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia. Nat Med 7 (2001) 444-451
21. Preudhomme C., Sagot C., Boissel N., Cayuela J.M., Tigaud I., de Botton S., et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 100 (2002) 2717-2723
22. Frohling S., Schlenk R.F., Stolze I., Bihlmayr J., Benner A., Kreitmeier S., et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22 4 (2004) 624-633
23. Antonson P., and Xanthopoulos K.G. Molecular cloning, sequence, and expression patterns of the human gene encoding CCAAT/enhancer binding protein α (C/EBPα). Biochem Biophys Res Commun 215 (1995) 106-113
24. Sugahara K., Iyama K.I., Kimura T., Sano K., Darlington G.J., Akiba T., et al. Mice lacking CCCAAT/enhancer-binding protein-alpha show hyperproliferation of alveolar type II cells and increased surfactant protein mRNAs. Cell Tissue Res 306 (2001) 57-63
25. Nord M., Cassel T.N., Braun H., and Suske G. Regulation of the Clara cell secretory protein/uteroglobin promoter in lung. Ann NY Acad Sci 923 (2000) 154-165
26. Cassel T.N., and Nord M. C/EBP transcription factors in the lung epithelium. Am J Physiol Lung Cell Mol Physiol 285 (2003) L773-L781
27. Flodby P., Barlow C., Kylefjord H., Ahrlund-Richter L., and Xanthopoulos K.G. Increased hepatic cell proliferation and lung abnormalities in mice deficient in CCAAT/enhancer binding protein alpha. J Biol Chem 271 (1996) 24753-24760
28. Basseres D.S., Levantini E., Ji H., Monti S., Elf S., Dayaram T., et al. Respiratory failure due to differentiation arrest and expansion of alveolar cells following lung-specific loss of the transcription factor C/EBPalpha in mice. Mol Cell Biol 26 3 (2006) 1109-1123
29. Halmos B., Huettner C.S., Kocher O., Ferenczi K., Karp D.D., and Tenen D.G. Down-regulation and antiproliferative role of C/EBPalpha in lung cancer. Cancer Res 62 (2002) 528-534
30. Tada Y., Brena R.M., Hackanson B., Morrison C., Otterson G.A., and Plass C. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein α activity in lung cancer. J Natl Cancer Inst 98 6 (2006) 396-406
31. Keller S.M., Adak S., Wagner H., Herskovic A., Komaki R., Brooks B.J., et al., Eastern Cooperative Oncology Group. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. N Engl J Med 343 17 (2000) 1217-1222
32. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
33. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50 (1966) 163-170
34. Costa D.B., Dayaram T., D'Alo F., Wouters B.J., Tenen D.G., Meyerson M., et al. C/EBPalpha mutations in lung cancer. Lung Cancer 53 (2006) 253-254
35. Shim M., Powers K.L., Ewing S.J., Zhu S., and Smart R.C. Diminished expression of C/EBPalpha in skin carcinomas is linked to oncogenic Ras and reexpression of C/EBPalpha in carcinoma cells inhibits proliferation. Cancer Res 65 (2005) 861-867
36. Olauseen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355 10 (2006) 983-991